| Project/Area Number |
16K20874
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Biological pharmacy
Experimental pathology
|
|---|
| Research Institution | Hokkaido University |
|---|
Principal Investigator |
Takei Norio 北海道大学, 産学・地域協働推進機構, 特任助教 (50523461)
|
|---|
| Project Period (FY) |
2016-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2017: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2016: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | GPCR / OR7C1 / CRISPR/Cas9 / 糖代謝 / 癌 / 嗅神経細胞 / cancer / 癌幹細胞 |
|---|
| Outline of Final Research Achievements |
OR7C1 is a G protein coupled receptor and expressed in cancer stem cell and suggested the possibility as a novel factor of poor prognosis. However, the function in cancer remain unclear. In this study, to uncover the importance of OR7C1 expression in cancer biology, we generated conventional OR7C1 knockout clones by using the CRISPR/Cas9 system. As a result, OR7C1 KO decreased tumorigenicity and metastasis in vivo and cell proliferation under specific medium conditions in vitro. In conclusion, our findings suggest that OR7C1 is predominantly activated under specific condition such as starvation and contributes to cancer progression. Collectively, OR7C1 could be used as both a diagnostic biomarker of cancer exacerbation and a therapeutic target.
|
